tesamorelin dosage body composition: Frequently asked questions

Discard it immediately and reconstitute a fresh vial. Tesamorelin stored above 8°C for more than 2 hours undergoes irreversible protein denaturation. The peptide chain breaks at specific amide bonds, creating fragments that cannot activate GHRH receptors. This degradation is not visible to the naked eye and cannot be detected by clarity or color changes. Injecting degraded peptide wastes money and delays your protocol timeline without providing therapeutic benefit. Temperature-excursion damage is the single most common reason patients report 'tesamorelin stopped working' after initial success.

No. Administer your regular 2mg dose at the next scheduled time and continue the protocol without adjustment. Doubling the dose creates a supraphysiological GH spike that increases adverse events (joint pain, edema) without compensating for the missed lipolytic signaling from the previous day. Missing 1-2 doses per month has minimal impact on total VAT reduction, but missing more than 3 consecutive doses resets the cumulative ATGL upregulation timeline by approximately 10 days. If you miss doses frequently due to travel or storage challenges, consider whether the protocol fits your lifestyle. Inconsistent dosing produces inconsistent results.

Verify three factors before concluding non-response: (1) Confirm you're storing reconstituted vials at 2-8°C consistently and using each vial within 14 days. (2) Measure baseline and current IGF-1. If your IGF-1 hasn't increased by at least 30-40 ng/mL from baseline, either the peptide is degraded or your pituitary GHRH receptors are downregulated. (3) Ensure you're measuring visceral adipose tissue correctly through DEXA or CT imaging. Waist circumference and body weight are unreliable proxies because tesamorelin preserves lean mass while reducing VAT, often resulting in stable weight despite significant body composition change. If all three factors check out and IGF-1 rose appropriately but VAT didn't decrease, you may be in the 15-20% of patients with high baseline GH status who respond minimally to GHRH analogs.

No. 1mg produces GH peaks of 4–6 ng/mL, which is below the threshold required to activate hormone-sensitive lipase in visceral adipocytes. You will spend weeks at a dose that does not produce meaningful VAT reduction. Adverse events (injection site reactions, transient oedema) occur at similar rates across all doses, so starting lower does not reduce side effect incidence. Begin at 2mg unless contraindicated.

No. Never double-dose. Tesamorelin stimulates a GH pulse that peaks 60–90 minutes post-injection and returns to baseline within 4–6 hours. Doubling the dose creates a supraphysiological GH spike that can trigger glucose intolerance and fluid retention without producing additional VAT reduction. If you miss a dose, resume your regular 2mg injection the following evening.

Your GH response will be blunted by 30–40% due to insulin-mediated GHRH receptor desensitisation. Postprandial insulin levels. Especially after carbohydrate intake. Suppress both GHRH receptor sensitivity and downstream GH secretion. The standard protocol requires at least 3 hours fasted before injection. If you inject post-meal, that dose is wasted. You cannot recover the effect with a second injection later.